|
US6376472B1
(en)
*
|
1996-07-08 |
2002-04-23 |
Aventis Pharmaceuticals, Inc. |
Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
|
|
GB9723590D0
(en)
*
|
1997-11-08 |
1998-01-07 |
Glaxo Group Ltd |
Chemical compounds
|
|
YU44900A
(sh)
|
1998-01-31 |
2003-01-31 |
Glaxo Group Limited |
Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
|
|
GB9813554D0
(en)
|
1998-06-23 |
1998-08-19 |
Glaxo Group Ltd |
Chemical compounds
|
|
AU750462B2
(en)
|
1998-06-23 |
2002-07-18 |
Glaxo Group Limited |
2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
|
|
US6713492B1
(en)
|
1998-11-25 |
2004-03-30 |
Daiichi Radioisotope Laboratories, Ltd. |
N-acyloxylated cycloalkyl compounds, composition containing the same and methods of use therefor
|
|
ES2228163T3
(es)
|
1998-12-31 |
2005-04-01 |
Aventis Pharmaceuticals Inc. |
Procedimiento para preparar derivados de desaza-adenosina n6-sustituidos.
|
|
GB0106867D0
(en)
*
|
2001-03-20 |
2001-05-09 |
Glaxo Group Ltd |
Process
|
|
US20030069423A1
(en)
*
|
2001-05-10 |
2003-04-10 |
Ayers Timothy A. |
Novel processes for the preparation of adenosine compounds and intermediates thereto
|
|
EP1258247A1
(en)
*
|
2001-05-14 |
2002-11-20 |
Aventis Pharma Deutschland GmbH |
Adenosine analogues for the treatment of insulin resistance syndrome and diabetes
|
|
FR2835186B1
(fr)
|
2002-01-28 |
2006-10-20 |
Aventis Pharma Sa |
Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
|
|
HUP0200849A2
(hu)
*
|
2002-03-06 |
2004-08-30 |
Sanofi-Synthelabo |
N-aminoacetil-2-ciano-pirrolidin-származékok, e vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
|
|
EP1375508A1
(en)
*
|
2002-06-27 |
2004-01-02 |
Aventis Pharma Deutschland GmbH |
N6-substituted adenosine analogues and their use as pharmaceutical agents
|
|
US7163937B2
(en)
|
2003-08-21 |
2007-01-16 |
Bristol-Myers Squibb Company |
Cyclic derivatives as modulators of chemokine receptor activity
|
|
FR2862969A1
(fr)
*
|
2003-11-28 |
2005-06-03 |
Oreal |
Procede de preparation de derives paraphenylenediamine a groupement pyrrolidinyle, substitue par un radical azote, et composes intermediaires
|
|
EP1574508A1
(de)
|
2004-01-30 |
2005-09-14 |
Lonza AG |
Verfahren zur Herstellung von Acetalen und Ketalen von 3-Amino-5-(hydroxymethyl)-cyclopentan-1,2-diolen, sowie deren Derivaten und Salzen
|
|
AR049384A1
(es)
|
2004-05-24 |
2006-07-26 |
Glaxo Group Ltd |
Derivados de purina
|
|
JP2006022045A
(ja)
*
|
2004-07-08 |
2006-01-26 |
Kaneka Corp |
光学活性１−ｔ−ブトキシカルボニル−３−アミノピロリジン塩の単離精製方法
|
|
GB0514809D0
(en)
|
2005-07-19 |
2005-08-24 |
Glaxo Group Ltd |
Compounds
|
|
US7671062B2
(en)
|
2006-07-28 |
2010-03-02 |
Bristol-Myers Squibb Company |
Modulators of chemokine receptor activity, crystalline forms and process
|
|
US7687508B2
(en)
|
2006-07-28 |
2010-03-30 |
Bristol-Myers Squibb Company |
Cyclic derivatives as modulators of chemokine receptor activity
|
|
US7629351B2
(en)
|
2006-07-28 |
2009-12-08 |
Bristol-Myers Squibb Company |
N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-2-oxo-3-(6-(trifluoromethyl)quinazolin-4-ylamino) pyrrolidin-1-yl)cyclohexyl)acetamide and other modulators of chemokine receptor activity, crystalline forms and process
|
|
DE102007002260A1
(de)
|
2007-01-16 |
2008-07-31 |
Sanofi-Aventis |
Verwendung von substituierten Pyranonsäurederivaten zur Herstellung von Medikamenten zur Behandlung des Metabolischen Syndroms
|
|
US8383812B2
(en)
|
2009-10-13 |
2013-02-26 |
Bristol-Myers Squibb Company |
N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-A][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes
|
|
BR112018014525A2
(pt)
*
|
2016-01-14 |
2018-12-11 |
Handok Inc |
compostos que antagonizam receptor de adenosina a3, método para preparação dos mesmos e aplicação médica dos mesmos
|
|
CN110627765B
(zh)
*
|
2019-10-14 |
2021-08-20 |
浙江乐普药业股份有限公司 |
一种替卡格雷关键中间体的制备方法
|
|
CN112047919B
(zh)
*
|
2020-09-16 |
2021-06-18 |
常州制药厂有限公司 |
一种替卡格雷中间体及其制备方法
|
|
KR102308854B1
(ko)
*
|
2021-02-26 |
2021-10-05 |
퓨쳐메디신 주식회사 |
카보사이클릭 뉴클레오사이드 유도체를 포함하는 코로나바이러스감염증-19 예방 및 치료용 약학적 조성물
|